These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 23148692)
1. Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer. Berdel B; Nieminen K; Soini Y; Tengström M; Malinen M; Kosma VM; Palvimo JJ; Mannermaa A BMC Cancer; 2012 Nov; 12():516. PubMed ID: 23148692 [TBL] [Abstract][Full Text] [Related]
2. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer. Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721 [TBL] [Abstract][Full Text] [Related]
3. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458 [TBL] [Abstract][Full Text] [Related]
4. Lectin histochemistry reveals SNA as a prognostic carbohydrate-dependent probe for invasive ductal carcinoma of the breast: a clinicopathological and immunohistochemical auxiliary tool. dos-Santos PB; Zanetti JS; Vieira-de-Mello GS; Rêgo MB; Ribeiro-Silva A A; Beltrão EI Int J Clin Exp Pathol; 2014; 7(5):2337-49. PubMed ID: 24966944 [TBL] [Abstract][Full Text] [Related]
5. Relationship Between Histone Deacetylase 3 (HDAC3) and Breast Cancer. Cui Z; Xie M; Wu Z; Shi Y Med Sci Monit; 2018 Apr; 24():2456-2464. PubMed ID: 29680858 [TBL] [Abstract][Full Text] [Related]
6. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950 [TBL] [Abstract][Full Text] [Related]
7. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Liu G; Bollig-Fischer A; Kreike B; van de Vijver MJ; Abrams J; Ethier SP; Yang ZQ Oncogene; 2009 Dec; 28(50):4491-500. PubMed ID: 19784073 [TBL] [Abstract][Full Text] [Related]
8. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Walter O; Prasad M; Lu S; Quinlan RM; Edmiston KL; Khan A Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680 [TBL] [Abstract][Full Text] [Related]
9. Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma. Sun LL; Holowatyj A; Xu XE; Wu JY; Wu ZY; Shen JH; Wang SH; Li EM; Yang ZQ; Xu LY Am J Cancer Res; 2013; 3(5):509-17. PubMed ID: 24224128 [TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival. Serra KP; Peres RM; Sarian LO; Vassallo J; Pinto GA; Silva GR; Soares FA; da Cunha IW; Espinola J; Bento AM; Del Corso LM; Derchain S Acta Histochem; 2016 Mar; 118(2):176-82. PubMed ID: 26791786 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab. Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of molecular classification of breast invasive ductal carcinoma. Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group. Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503 [TBL] [Abstract][Full Text] [Related]
14. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma. Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715 [TBL] [Abstract][Full Text] [Related]
16. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614 [TBL] [Abstract][Full Text] [Related]
17. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma. Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827 [TBL] [Abstract][Full Text] [Related]
18. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480 [TBL] [Abstract][Full Text] [Related]
19. Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031 [TBL] [Abstract][Full Text] [Related]
20. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma. Chen Y; Song J; Jiang Y; Yu C; Ma Z Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]